OmniAb Investor Presentation Deck
Our Business
LEVERAGING OUR PROPRIETARY DISCOVERY TECHNOLOGY PLATFORM WORLDWIDE
dT Td
Technology Offering Addresses Most
Critical Challenges of Discovery
Create, Screen, Deliver antibodies leveraging
industry's only 4-species platform with
differentiated tech and core competencies
Leading and Proven
Technology
74 partners have access to OmniAb antibodies
305 active programs with 3 product approvals
Sources: Clarivate Analytics Cortellis database.
POISED FOR
GROWTH
TO MEET A
GLOBAL
INDUSTRY
NEED
One of the Largest Greenfields
in the Pharma Industry
$279 billion total addressable market
for antibodies by 2025
Innovation and Intelligent
Expansion of Our Technology
New technology launches in 2023 -
OmniDeep™M, OmnidAb™
3
prilic
OmniAbView entire presentation